(39) to redirect T cells to EphA2-positive GBM in vitro with the aim of identifying and killing EphA2-positive glioma cells and glioma-initiating cells, as well as inducing tumor induction in an in situ xenografted GBM with Severe Combined Immunodeficiency (SCID) mouse model of regression. The gene discussed is EPHA2; the disease is central nervous system cancer.